<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Contraception: Hormonal contraception and blood pressure
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Contraception: Hormonal contraception and blood pressure
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Contraception: Hormonal contraception and blood pressure
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jan Basile, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael J Bloch, MD, FACP, FASH, FSVM, FNLA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            George L Bakris, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William J Elliott, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Courtney A Schreiber, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Karen Law, MD, FACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristen Eckler, MD, FACOG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 30, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3431144770">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hormonal contraceptives contain estrogens and/or progestins that can impact the cardiovascular system, including effects on blood pressure. These effects depend, in part, upon the drug, dose, and route of delivery, and they are particularly important when considering treatment options for individuals with underlying hypertensive disorders.
        </p>
        <p>
         This topic will review our approach to the management of hormonal contraception for individuals with hypertension, as well as the management of individuals who develop an elevation in blood pressure after initiating hormonal contraception. Of note, this content does not apply to estrogen-containing hormone therapy for menopause. Overview discussions of contraception selection and menopausal hormone therapy can be found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">
          "Contraception: Counseling and selection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7427.html" rel="external">
          "Menopausal hormone therapy: Benefits and risks"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7409.html" rel="external">
          "Menopausal hormone therapy and cardiovascular risk"
         </a>
         .)
        </p>
        <p>
         In this topic, when discussing study results, we will use the term "women" as it is used in the studies presented. We recognize that not all genetic females or people who use contraception identify as women, and we encourage the reader to consider the specific counseling and treatment needs of transgender and gender nonbinary individuals.
        </p>
        <p class="headingAnchor" id="H629056567">
         <span class="h1">
          DEFINITION AND DIAGNOSIS OF HYPERTENSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Proper blood pressure measurement technique and interpretation is essential in the diagnosis and management of hypertension.
        </p>
        <p class="headingAnchor" id="H4041223796">
         <span class="h2">
          Definition of hypertension
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is not universal agreement as to the definition of hypertension. For this document, we use systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg. Our rationale is that data specific to females with systolic pressure 130 to 139 mmHg or diastolic pressure 80 to 89 mmHg, and the impact of contraception on blood pressure in this group, are lacking. While using a cutoff of 130/80 as the definition may be important for other cardiovascular outcomes, for the purposes of contraceptive selection, we and other organizations believe that individuals with Stage I hypertension, as described below, should not be denied contraceptive options based solely on blood pressure measurements until data specific to this group are available [
         <a href="#rid1">
          1-3
         </a>
         ]. The definition of hypertension is presented in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3852.html" rel="external">
          "Overview of hypertension in adults", section on 'Definitions'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Blood pressure ≥130/80
         </strong>
         – The following definitions and staging system for hypertension were suggested in 2017 by the American College of Cardiology/American Heart Association (ACC/AHA)  (
         <a class="graphic graphic_table graphicRef131445" href="/z/d/graphic/131445.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Normal blood pressure
         </strong>
         – Systolic &lt;120 mmHg and diastolic &lt;80 mmHg
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Elevated blood pressure
         </strong>
         – Systolic 120 to 129 mmHg and diastolic &lt;80 mmHg
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hypertension
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Stage 1
         </strong>
         – Systolic 130 to 139 mmHg
         <strong>
          or
         </strong>
         diastolic 80 to 89 mmHg
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Stage 2
         </strong>
         – Systolic at least 140 mmHg
         <strong>
          or
         </strong>
         diastolic at least 90 mmHg
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If there is a disparity in category between the systolic and diastolic pressures, the
         <strong>
          higher value
         </strong>
         determines the stage. In clinical practice, patients who are taking medications for hypertension are usually defined as having hypertension, specifically "treated hypertension," regardless of their observed blood pressure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Blood pressure ≥140/90
         </strong>
         – European guidance and guidelines from the American Academy of Family Physicians, the American College of Physicians, and the American College of Obstetricians and Gynecologists differ from that of the ACC/AHA  (
         <a class="graphic graphic_table graphicRef119219" href="/z/d/graphic/119219.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid4">
          4-8
         </a>
         ]. The European Society of Cardiology and European Society of Hypertension define hypertension, using office-based blood pressure, as a systolic pressure ≥140 mmHg or diastolic pressure ≥90 mmHg [
         <a href="#rid6">
          6,8,9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1752389912">
         <span class="h2">
          Diagnosing hypertension
         </span>
         <span class="headingEndMark">
          —
         </span>
         Making the diagnosis of hypertension requires the integration of multiple blood pressure readings, the use of appropriate blood pressure measurement technique  (
         <a class="graphic graphic_table graphicRef115862" href="/z/d/graphic/115862.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef115863" href="/z/d/graphic/115863.html" rel="external">
          table 4
         </a>
         ), and also the use of blood pressure measurements made outside of the usual office setting (out-of-office blood pressure measurement)  (
         <a class="graphic graphic_algorithm graphicRef105050" href="/z/d/graphic/105050.html" rel="external">
          algorithm 1
         </a>
         ). This is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3852.html" rel="external">
          "Overview of hypertension in adults", section on 'Making the diagnosis of hypertension'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H187877273">
         <span class="h1">
          EFFECT OF EXOGENOUS ESTROGENS AND PROGESTINS ON BLOOD PRESSURE
         </span>
        </p>
        <p class="headingAnchor" id="H1367179189">
         <span class="h2">
          Estrogens
         </span>
        </p>
        <p class="headingAnchor" id="H2672744018">
         <span class="h3">
          Impact on blood pressure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some individuals who take products with pharmacologic levels of estrogen (ie, contraceptives) may experience increases in blood pressure. The blood pressure effect is dose dependent. Products with physiologic levels of estrogen, such as hormone therapy for menopause, do not increase blood pressure. (See
         <a class="local">
          'Menopausal hormone therapy'
         </a>
         below.)
        </p>
        <p>
         Based on data from users of combined estrogen-progestin oral contraceptive (COC) pills, any rise in blood pressure while taking COCs is usually mild, although some individuals may have more significant increases in blood pressure, and hypertensive emergencies may rarely occur [
         <a href="#rid10">
          10,11
         </a>
         ]. Long-term use of COCs containing ethinyl estradiol and progestin at contemporary doses will slightly increase systemic blood pressure in most individuals, although the absolute increase is small and the development of overt hypertension is infrequent [
         <a href="#rid10">
          10,12,13
         </a>
         ]. Most combined hormonal contraceptives contain ethinyl estradiol, but estradiol valerate, estradiol as a hemihydrate, and estetrol are also used  (
         <a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">
          table 5
         </a>
         ); available data mostly reflect contraceptives containing ethinyl estradiol.
        </p>
        <p>
         A 1996 prospective cohort study including 68,000 healthy nurses aged 25 to 42 years taking multiple types of COCs reported [
         <a href="#rid10">
          10
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among all users, the mean increases in systolic and diastolic blood pressure were small in adjusted analysis (0.7 mmHg, 95% CI 0.4-1.0; and 0.4 mmHg, 95% CI 0.2-0.6, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In users of COCs containing ≤30 mcg ethinyl estradiol equivalents, the risk of developing hypertension remained greater for current users compared with never-users in adjusted analysis (relative risk 1.9, 95% CI 1.5-2.5).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The risk of hypertension with COC use increased in a dose-dependent fashion across low (≤30 mcg ethinyl estradiol equivalents), medium (&gt;30 to ≤50 mcg ethinyl estradiol equivalents), and high (&gt;50 mcg ethinyl estradiol equivalents) dose pills.
        </p>
        <p>
        </p>
        <p>
         By contrast, earlier COCs that contained at least 50 mcg of estrogen were reported to induce hypertension in approximately 5 percent of users [
         <a href="#rid14">
          14-17
         </a>
         ]. Cessation of COCs typically leads to a return to an individual's baseline blood pressure within three months [
         <a href="#rid14">
          14
         </a>
         ]. COCs that contain
         <a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">
          drospirenone
         </a>
         , a progestin with antimineralocorticoid diuretic effects, appear to reduce the blood pressure elevating effect of estrogen  (
         <a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid18">
          18-20
         </a>
         ]. Detailed discussion of estrogen types and doses used in COCs is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Estrogen'
         </a>
         .)
        </p>
        <p>
         The mechanisms responsible for the hypertensive effect of COCs are incompletely understood [
         <a href="#rid21">
          21
         </a>
         ]. The renin-angiotensin system (RAS) may be involved since estrogen stimulates the hepatic production of renin substrate (angiotensinogen) [
         <a href="#rid22">
          22
         </a>
         ], but the interaction among estrogen and
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          progesterone
         </a>
         and the RAS are complex. Activation of the sympathetic nervous system may also be involved. However, in a study comparing individuals taking combined hormonal contraception with non-users, no changes in muscle sympathetic nerve activity or systemic hemodynamics were reported [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2884037885">
         <span class="h3">
          Non-oral estrogen-containing contraceptives
         </span>
         <span class="headingEndMark">
          —
         </span>
         Non-oral estrogen-progestin hormonal contraceptives include vaginal rings, transdermal contraceptive patches, and combined estrogen-progesterone injections (available outside of the United States and Canada). The effect of these agents on blood pressure may be more modest than with COCs, although available data are limited [
         <a href="#rid24">
          24,25
         </a>
         ]. The impact of these methods on other cardiovascular risk factors appears to be similar to COCs. However, some data suggest an increased risk of venous thromboembolism (VTE) for users of combined estrogen-progestin contraceptive patches compared with users of lower-dose COCs (≤35 mcg ethinyl estradiol equivalents). This is reviewed in detail elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16682.html" rel="external">
          "Contraception: Hormonal contraceptive vaginal rings", section on 'Cardiovascular and thromboembolic events'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5425.html" rel="external">
          "Contraception: Transdermal contraceptive patches", section on 'Risk of venous thrombotic events'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2750143778">
         <span class="h3">
          Impact on other cardiovascular risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Combined estrogen-progestin contraceptives can increase the risk of thromboembolic events (both venous and arterial), myocardial infarction, and stroke, although the absolute risk remains low for most individuals. The risk of VTE events rises with increasing estrogen doses  (
         <a class="graphic graphic_table graphicRef121107" href="/z/d/graphic/121107.html" rel="external">
          table 6
         </a>
         ). These changes are reviewed in detail in related content:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Venous thromboembolism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Myocardial infarction and stroke'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Lipid changes and metabolic effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2030601164">
         <span class="h2">
          Progestins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Progestin-only contraceptives, from highest to lowest efficacy, include implants, levonorgestrel-releasing intrauterine devices (IUDs), depot
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         (DMPA) injection, and progestin-only pills (POPs)  (
         <a class="graphic graphic_figure graphicRef119765" href="/z/d/graphic/119765.html" rel="external">
          figure 1
         </a>
         ). While progestin-only contraceptives are generally not associated with elevations in blood pressure, some may impact other cardiovascular risks. These data are reviewed separately by formulation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">
          "Contraception: Etonogestrel implant", section on 'Risk of thromboembolic event'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/118540.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Cardiovascular and thromboembolic risk'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5461.html" rel="external">
          "Contraception: Progestin-only pills (POPs)", section on 'Risks'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H182174404">
         <span class="h2">
          Nonhormonal contraceptives
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonhormonal contraceptives do not impact blood pressure or other cardiovascular disease (CVD) risks. These options include the
         <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">
          copper IUD
         </a>
         , condoms (internal and external), and pericoital methods (ie, diaphragm, cervical cap, contraceptive sponge, and spermicide). Permanent contraception (eg, female or male sterilization procedures) may be an option for individuals who have completed childbearing and do not have other risk factors for poor surgical outcome. Efficacy varies by method  (
         <a class="graphic graphic_figure graphicRef119765" href="/z/d/graphic/119765.html" rel="external">
          figure 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">
          "Intrauterine contraception: Background and device types", section on 'Copper IUD'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5463.html" rel="external">
          "External (formerly male) condoms"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5471.html" rel="external">
          "Internal (formerly female) condoms"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3265.html" rel="external">
          "Pericoital (on demand) contraception: Diaphragm, cervical cap, spermicides, and sponge"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Information on contraceptive counseling and selection is presented in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">
          "Contraception: Counseling and selection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H522679904">
         <span class="h2">
          Menopausal hormone therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Replacement doses of estrogen present in systemic menopausal hormone therapy are physiologic and have little clinically meaningful effect on blood pressure [
         <a href="#rid26">
          26-29
         </a>
         ]. Transdermal estrogen preparations are associated with lower risk of hypertension compared with oral formulations [
         <a href="#rid30">
          30
         </a>
         ]. The impact of menopausal hormone therapy on cardiovascular parameters is presented in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7409.html" rel="external">
          "Menopausal hormone therapy and cardiovascular risk", section on 'Blood pressure'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1705141130">
         <span class="h1">
          EVALUATION OF PATIENTS WITH HYPERTENSION
         </span>
        </p>
        <p class="headingAnchor" id="H4037976993">
         <span class="h2">
          Assess other medical conditions and comorbidities
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with hypertension, additional medical conditions and comorbidities must also be taken into account when considering prescribing hormonal contraception  (
         <a class="graphic graphic_table graphicRef77599" href="/z/d/graphic/77599.html" rel="external">
          table 7
         </a>
         ) [
         <a href="#rid31">
          31
         </a>
         ]. We, and other experts, use both the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) comprehensive tables of medical conditions and personal characteristics that may affect contraceptive choice [
         <a href="#rid1">
          1,2
         </a>
         ]. While the advisory documents are generally similar, clinicians should select whichever better fits their population. Summary tables can be found through the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=3827" target="_blank">
          CDC's Summary Chart of US Medical Eligibility Criteria
         </a>
         and the
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F181468%2F9789241549158_eng.pdf%3Fsequence%3D9&amp;token=6nhhnZb0mtkVJwS3WOakPA5w7GkgerBCs7nrlFUitrR39lCGuBWfNLRXexATvnXkkXhjZwURagZbVOoo0qtiepjUv8Riew8Ltoc8ATBTzvUodc7F1ZodE778QnzeChim&amp;TOPIC_ID=3827" target="_blank">
          WHO Medical Eligibility Criteria for Contraceptive Use 2015
         </a>
         .
        </p>
        <p>
         Specific factors we consider when evaluating contraceptive options in individuals with hypertension include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient age (ie, &lt;40 versus ≥40 years of age). Although the American College of Obstetrics and Gynecology (ACOG) guidelines suggest using age 35 as a criterion in considering the risk of hormonal contraception, others, such as the WHO and CDC, use age 40 [
         <a href="#rid1">
          1,2,7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of tobacco products, including traditional cigarette or cigar smoking, e-cigarettes (ie, vaping), water pipes (ie, hookahs), and smokeless tobacco.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adequacy of blood pressure control.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other cardiovascular disease (CVD) risk factors:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hyperlipidemia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Diabetes
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Obesity (body mass index [BMI] &gt;30 kg/m
         <sup>
          2
         </sup>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Family history of premature CVD
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Physical inactivity
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of CVD:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Venous thromboembolism (VTE)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Complicated valvular disease
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ischemic heart disease
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Known thrombogenic variations
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Stroke
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1860466343">
         <span class="h2">
          Compare with risks of pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         When considering risks associated with hormonal contraceptives, the patient and clinician must balance potential risks against the risks of unintended pregnancy, the risks of pregnancy itself (eg, 10-fold greater risk of VTE  (
         <a class="graphic graphic_table graphicRef121107" href="/z/d/graphic/121107.html" rel="external">
          table 6
         </a>
         )), and the greater risks of poor obstetric and neonatal outcomes for individuals with hypertension in pregnancy (eg, preterm delivery, small-for-gestational age). (See
         <a class="medical medical_review" href="/z/d/html/116432.html" rel="external">
          "Chronic hypertension in pregnancy: Prenatal and postpartum care", section on 'Risks of chronic hypertension in pregnancy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1676140198">
         <span class="h2">
          Identify unacceptable risks to hormonal contraception
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based upon the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=3827" target="_blank">
          CDC's Summary Chart of US Medical Eligibility Criteria
         </a>
         and the
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F181468%2F9789241549158_eng.pdf%3Fsequence%3D9&amp;token=6nhhnZb0mtkVJwS3WOakPA5w7GkgerBCs7nrlFUitrR39lCGuBWfNLRXexATvnXkkXhjZwURagZbVOoo0qtiepjUv8Riew8Ltoc8ATBTzvUodc7F1ZodE778QnzeChim&amp;TOPIC_ID=3827" target="_blank">
          WHO Medical Eligibility Criteria for Contraceptive Use 2015
         </a>
         Category 4 rating (unacceptable health risk [method not to be used]), combined hormonal contraception is
         <strong>
          not
         </strong>
         used in individuals with the following [
         <a href="#rid1">
          1,2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Uncontrolled hypertension (systolic ≥160 mmHg or diastolic ≥100 mmHg)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age ≥35 years
         <strong>
          and
         </strong>
         smoking ≥15 cigarettes per day
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multiple risk factors for arterial CVD (such as older age, smoking, diabetes, nephropathy, and hypertension)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute VTE/pulmonary embolism (PE) or history of DVT/PE at high risk for recurrence and not on anticoagulation (see
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Venous thromboembolism'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5479.html" rel="external">
          "Contraception: Counseling for women with inherited thrombophilias", section on 'Personal history of venous thrombosis'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Known ischemic heart disease
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of stroke
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complicated valvular heart disease (pulmonary hypertension, risk for atrial fibrillation, history of subacute bacterial endocarditis)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Current breast cancer
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of breast cancer (although there are some exceptions) (see
         <a class="medical medical_review" href="/z/d/html/15781.html" rel="external">
          "Approach to the patient following treatment for breast cancer", section on 'Contraception after breast cancer'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe (decompensated) cirrhosis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatocellular adenoma or malignant hepatoma
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Migraine with aura (although there are limited exceptions) (see
         <a class="medical medical_review" href="/z/d/html/5441.html" rel="external">
          "Estrogen-associated migraine headache, including menstrual migraine"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diabetes mellitus of &gt;20 years' duration, or diabetes mellitus of any duration complicated by diabetic nephropathy, retinopathy, or neuropathy
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1969246421">
         <span class="h1">
          APPROACH TO CONTRACEPTION FOR INDIVIDUALS WITH HYPERTENSION
         </span>
        </p>
        <p class="headingAnchor" id="H3312808759">
         <span class="h2">
          Counseling issues
         </span>
        </p>
        <p class="headingAnchor" id="H321238149">
         <span class="h3">
          Recognize need for counseling
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite the risks associated with pregnancy in patients with hypertension, one database study of over 8000 individuals at risk for unintended pregnancy reported that nearly 75 percent of hypertensive individuals and 80 percent of individuals without hypertension did not receive contraceptive counseling (weighted proportion 0.26, 95% CI 0.21-0.32 for hypertensive individuals; weighted proportion 0.21, 95% CI 0.19-0.22 for nonhypertensive individuals) [
         <a href="#rid32">
          32
         </a>
         ]. For patients with hypertension, Black individuals were 13 percentage points less likely to receive counseling compared with White counterparts, after adjusting for confounders (difference in difference -0.13, 95% CI -0.23 to -0.03).
        </p>
        <p class="headingAnchor" id="H895780612">
         <span class="h3">
          Adjust for medical comorbidities
         </span>
         <span class="headingEndMark">
          —
         </span>
         We, and other experts, use the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=3827" target="_blank">
          CDC's Summary Chart of US Medical Eligibility Criteria
         </a>
         and the
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F181468%2F9789241549158_eng.pdf%3Fsequence%3D9&amp;token=6nhhnZb0mtkVJwS3WOakPA5w7GkgerBCs7nrlFUitrR39lCGuBWfNLRXexATvnXkkXhjZwURagZbVOoo0qtiepjUv8Riew8Ltoc8ATBTzvUodc7F1ZodE778QnzeChim&amp;TOPIC_ID=3827" target="_blank">
          WHO Medical Eligibility Criteria for Contraceptive Use 2015
         </a>
         comprehensive tables of medical conditions and personal characteristics to help guide contraceptive choice [
         <a href="#rid1">
          1,2
         </a>
         ]. In these documents, hypertension is defined as systolic &gt;140 or diastolic &gt;90 mmHg. While the advisory documents are generally similar, clinicians should select whichever better fits their population.
        </p>
        <p class="headingAnchor" id="H306597882">
         <span class="h2">
          Controlled hypertension
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many individuals with hypertension can safely take hormonal contraception, even if they take antihypertensive medication, provided their blood pressure is controlled (ie, blood pressure &lt;140/90 mm/Hg with medication). (See
         <a class="local">
          'Definition of hypertension'
         </a>
         above.)
        </p>
        <p>
         In addition, they should be otherwise healthy and without additional CVD risk factors, continue on antihypertensive therapy (if applicable), and have their blood pressure well monitored [
         <a href="#rid1">
          1,2,7
         </a>
         ]. One limitation of this guidance is that the WHO and CDC guidelines use a blood pressure cutoff of &lt;140/90 mmHg and do not address individuals with stage 1 hypertension (130 to139 mmHg/80 to 89 mmHg) as a distinct treatment group. Until data specific to individuals with stage 1 hypertension are available, we continue to use the cutoff of 140/90 mmHg [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H641620703">
         <span class="h3">
          Age &lt;40 years
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals who are &lt;40 years of age with adequately controlled hypertension (ie, &lt;140/90 mmHg), who are otherwise healthy, and who do not have other CVD risk factors or established CVD, may be offered any contraceptive method  (
         <a class="graphic graphic_figure graphicRef119765" href="/z/d/graphic/119765.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ]. However, contraceptive selection must balance the patient's contraceptive goals, potential impact of the contraceptive on the patient's hypertensive disorder, contraceptive efficacy, and potential non-contraceptive benefits (eg, reduction of dysmenorrhea or treatment of endometriosis), among other variables. (See
         <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">
          "Contraception: Counseling and selection"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         For patients with adequately controlled hypertension who have no absolute contraindication to hormonal contraception (see
         <a class="local">
          'Identify unacceptable risks to hormonal contraception'
         </a>
         above), we counsel patients that the lowest- to higher-risk hormonal methods include [
         <a href="#rid1">
          1,2
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          No restrictions
         </strong>
         – All levonorgestrel-releasing intrauterine devices (IUDs), progestin implants, and progestin-only pills (POPs).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Advantages generally outweigh risks
         </strong>
         – Depot
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         (DMPA).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risks of unclear magnitude
         </strong>
         – Combined estrogen-progestin contraceptives, including oral pills, transdermal patches, vaginal rings, and injections.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While both the WHO and the CDC label these medications with the statement "theoretical or proven risks usually outweigh the advantages," data specific to individuals with stage 1 hypertension (systolic 130 to 139 mmHg
         <strong>
          or
         </strong>
         diastolic 80 to 89 mmHg) are lacking. Both the WHO and CDC define hypertension as systolic &gt;140 mmHg and diastolic &gt;90 mmHg. In our practice, otherwise healthy patients with elevated blood pressure, stage 1 hypertension, or pharmacologically treated hypertension &lt;140/90 mmHg are potentially candidates for estrogen-containing contraceptives. Those who elect to use estrogen-progestin oral pills are prescribed pills containing 35 mcg of estrogen or less  (
         <a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2614078027">
         <span class="h4">
          Blood pressure monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Blood pressure checks are performed based on the type of contraceptive selected. Individuals who elect contraception that does not contain estrogen have their blood pressure repeated at routine visits. For individuals who elect combined estrogen-progestin contraception, we re-evaluate blood pressure two to four weeks after initiation, then at follow-up visits every six months; blood pressure evaluation can be performed through out-of-office or in-office measurement. (See
         <a class="medical medical_review" href="/z/d/html/3879.html" rel="external">
          "Blood pressure measurement in the diagnosis and management of hypertension in adults", section on 'Our approach to measuring blood pressure'
         </a>
         .)
        </p>
        <p>
         If the patient's blood pressure increases significantly while on any hormonal contraception:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We offer a different, non-estrogen hormonal contraceptive or a nonhormonal method (eg,
         <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">
          copper IUD
         </a>
         , condoms, pericoital contraceptives)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         After contraceptive switch, we monitor blood pressure to ensure a return to pretreatment values (typically within three months) [
         <a href="#rid14">
          14
         </a>
         ]. If elevated blood pressure persists, further evaluation and treatment is warranted. (See
         <a class="medical medical_review" href="/z/d/html/3849.html" rel="external">
          "Initial evaluation of adults with hypertension"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">
          "Choice of drug therapy in primary (essential) hypertension"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H659274618">
         <span class="h3">
          Age ≥40 years
         </span>
         <span class="headingEndMark">
          —
         </span>
         For individuals ≥40 years of age with adequately controlled hypertension (ie, &lt;140/90 mmHg) who are otherwise healthy and without other CVD risk factors or CVD, and with no absolute contraindication to hormonal contraception, we suggest non-estrogen contraceptives, although estrogen-containing contraceptives may be appropriate in select patients. Contraindications to hormonal contraception are reviewed above. (See
         <a class="local">
          'Identify unacceptable risks to hormonal contraception'
         </a>
         above.)
        </p>
        <p>
         Our approach includes the following [
         <a href="#rid1">
          1,2,7
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          No restrictions
         </strong>
         – All levonorgestrel-releasing IUDs, progestin implants, and POPs as well as all
         <strong>
          non
         </strong>
         hormonal contraceptives. (See
         <a class="local">
          'Nonhormonal contraceptives'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Advantages generally outweigh risks
         </strong>
         – Depot
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         (DMPA).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         does not impact blood pressure, it may increase the risk of thromboembolic events and cause unfavorable changes in lipid metabolism. Based on these theoretical concerns, DMPA is less preferred in this population given the availability of alternate options. However, as outcome data for individuals ≥40 years and controlled hypertension are lacking, DMPA can be reasonably used in appropriately counseled patients. (See
         <a class="medical medical_review" href="/z/d/html/118540.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Cardiovascular and thromboembolic risk'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risks (theoretical or proven) generally outweigh benefits
         </strong>
         – Combined estrogen-progestin contraceptives, including oral pills, transdermal patches, vaginal rings, and injections.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although there are limited data in this population, we generally do not prescribe these agents for such individuals because of the increased risk associated with multiple CVD risk factors (ie, older age and hypertension) and the availability of highly effective non-estrogen contraceptives [
         <a href="#rid1">
          1,2
         </a>
         ]. In appropriately counseled patients, however, combined estrogen-progestin contraceptives may be used if alternative contraceptive options are not acceptable to the patient or if significant non-contraceptive benefits exist with use of combined hormonal contraception (eg, reduction of pelvic pain associated with endometriosis). Patients who elect to use estrogen-progestin oral pills should only be prescribed pills containing 35 mcg of estrogen or less  (
         <a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H606166336">
         <span class="h4">
          Blood pressure monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Blood pressure checks are performed based on the type of contraceptive selected. For individuals using progestin-only methods, we check blood pressure at routine visits. For the rare individual ≥40 years with controlled hypertension who starts combined estrogen-progestin contraception, we re-evaluate blood pressure in two to four weeks after initiation, then at follow-up visits every six months; blood pressure evaluation can be performed through out-of-office or in-office measurement. (See
         <a class="medical medical_review" href="/z/d/html/3879.html" rel="external">
          "Blood pressure measurement in the diagnosis and management of hypertension in adults", section on 'Our approach to measuring blood pressure'
         </a>
         .)
        </p>
        <p>
         If blood pressure increases while on hormonal contraception:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We discontinue hormonal agents, and offer nonhormonal contraceptive methods (eg,
         <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">
          copper IUD
         </a>
         , condoms, pericoital contraception).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We monitor blood pressure to ensure return to pretreatment values (this typically occurs within three months) [
         <a href="#rid14">
          14
         </a>
         ]. If elevated blood pressure persists, further evaluation and treatment is warranted. (See
         <a class="medical medical_review" href="/z/d/html/3849.html" rel="external">
          "Initial evaluation of adults with hypertension"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">
          "Choice of drug therapy in primary (essential) hypertension"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1336573227">
         <span class="h2">
          Uncontrolled hypertension
         </span>
         <span class="headingEndMark">
          —
         </span>
         For individuals of any age with uncontrolled hypertension (blood pressure ≥140/90 mmHg, including those with blood pressure ≥160/100 mmHg), further evaluation and management of hypertension is warranted. (See
         <a class="medical medical_review" href="/z/d/html/3819.html" rel="external">
          "Treatment of resistant hypertension"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3830.html" rel="external">
          "Management of severe asymptomatic hypertension (hypertensive urgencies) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">
          "Choice of drug therapy in primary (essential) hypertension"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3862.html" rel="external">
          "Evaluation of secondary hypertension"
         </a>
         .)
        </p>
        <p>
         For these patients, we take the following approach to contraceptive counseling regardless of age group [
         <a href="#rid2">
          2,7
         </a>
         ]:
        </p>
        <p class="headingAnchor" id="H2359697892">
         <span class="h3">
          Choice of contraceptive
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          No restrictions
         </strong>
         – All
         <strong>
          non
         </strong>
         hormonal contraceptives are designated for use without restriction [
         <a href="#rid2">
          2,7
         </a>
         ]. The nonhormonal
         <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">
          copper IUD
         </a>
         (copper 380 mm
         <sup>
          2
         </sup>
         IUD) does not impact blood pressure and is one of the most effective contraceptive options  (
         <a class="graphic graphic_figure graphicRef119765" href="/z/d/graphic/119765.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="local">
          'Nonhormonal contraceptives'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">
          "Intrauterine contraception: Background and device types"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Advantages generally outweigh risks
         </strong>
         – Progestin-only contraceptives can be used in select individuals with no other contraindications to progestins [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The levonorgestrel-releasing IUDs,
         <a class="drug drug_general" data-topicid="8870" href="/z/d/drug information/8870.html" rel="external">
          etonogestrel implant
         </a>
         , and POPs are generally considered acceptable, even for patients with hypertension.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">
          "Intrauterine contraception: Background and device types"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">
          "Contraception: Etonogestrel implant", section on 'Risk of thromboembolic event'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5461.html" rel="external">
          "Contraception: Progestin-only pills (POPs)", section on 'Risks'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Depot
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         (DMPA) injection may be reasonably used in poorly controlled hypertensive individuals with no other cardiovascular risk factors and no history of stroke. DMPA injection does not impact blood pressure, but there are data suggesting it may contribute to or cause an unfavorable lipid profile and increase thromboembolic risk. However, the absolute risk of thromboembolic risk with DMPA injection is not known. (See
         <a class="medical medical_review" href="/z/d/html/118540.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Cardiovascular and thromboembolic risk'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risks (theoretical or proven) generally outweigh benefits
         </strong>
         – Estrogen-containing contraceptives, including oral pills, transdermal patches, vaginal rings, and injections, are generally avoided in individuals with blood pressure in the range of 130 to 159 mmHg/80 to 99 mmHg [
         <a href="#rid1">
          1,2,7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, in some patients with blood pressure in the lower range of hypertension, combined estrogen-progestin contraceptives may be used if alternative contraceptive options are not acceptable to the patient or if significant non-contraceptive benefits exist with use of combined hormonal contraception. Such patients should only be prescribed pills containing 35 mcg of estrogen or less  (
         <a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unacceptable risk
         </strong>
         – For patients with poorly controlled hypertension (ie, blood pressure ≥160/100 mmHg), we do
         <strong>
          not
         </strong>
         use combined estrogen-progestin contraceptives (oral pills, transdermal patches, vaginal rings, and injections) [
         <a href="#rid1">
          1,2,7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H297275573">
         <span class="h3">
          Blood pressure check
         </span>
         <span class="headingEndMark">
          —
         </span>
         Repeat blood pressure checks are performed based on the type of contraceptive selected.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For individuals using progestin-only methods, we check blood pressure at routine visits.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For the rare individual ≥40 years with uncontrolled hypertension who starts combined estrogen-progestin contraception, we re-evaluate blood pressure in two to four weeks after initiation, then at follow-up visits every six months; blood pressure evaluation can be performed through out-of-office or in-office measurement. (See
         <a class="medical medical_review" href="/z/d/html/3879.html" rel="external">
          "Blood pressure measurement in the diagnosis and management of hypertension in adults", section on 'Our approach to measuring blood pressure'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         If blood pressure increases while on hormonal contraception (progestin-only or estrogen-containing):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We discontinue hormonal agents and offer nonhormonal contraceptive methods (eg,
         <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">
          copper IUD
         </a>
         , condoms, pericoital contraception). (See
         <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">
          "Intrauterine contraception: Background and device types", section on 'Copper IUD'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5471.html" rel="external">
          "Internal (formerly female) condoms"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5463.html" rel="external">
          "External (formerly male) condoms"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3265.html" rel="external">
          "Pericoital (on demand) contraception: Diaphragm, cervical cap, spermicides, and sponge"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We monitor blood pressure to ensure return to pretreatment values (this typically occurs within three months) [
         <a href="#rid14">
          14
         </a>
         ]. If elevated blood pressure persists, further evaluation and treatment, including evaluation of resistant hypertension, is warranted. (See
         <a class="medical medical_review" href="/z/d/html/3849.html" rel="external">
          "Initial evaluation of adults with hypertension"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">
          "Choice of drug therapy in primary (essential) hypertension"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3818.html" rel="external">
          "Definition, risk factors, and evaluation of resistant hypertension"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3819.html" rel="external">
          "Treatment of resistant hypertension"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2117174130">
         <span class="h1">
          INDIVIDUALS WITHOUT HYPERTENSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         This grouping includes patients with normal (systolic &lt;120 mmHg and diastolic &lt;80 mmHg) and elevated blood pressure (systolic 120 to 129 mmHg and diastolic &lt;80 mmHg). (See
         <a class="local">
          'Definition of hypertension'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1057903358">
         <span class="h2">
          Risk of developing hypertension
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most individuals without hypertension (including those with normal blood pressure and elevated blood pressure)  (
         <a class="graphic graphic_table graphicRef131445" href="/z/d/graphic/131445.html" rel="external">
          table 1
         </a>
         ), the development of hypertension is unusual with contraceptives containing lower doses of estrogen (ie, ≤35 mcg estradiol or equivalent); the benefits of these agents generally outweigh the potential risk of medication-induced hypertension  (
         <a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid3">
          3,10
         </a>
         ]. Based on a study of estrogen-progestin oral contraceptive pills, the modest reported increases in the relative risk of hypertension with estrogen-containing contraceptives did not translate into increases in long-term overall mortality [
         <a href="#rid33">
          33
         </a>
         ]. Hormonal contraception, including estrogen-containing products, can be offered from menarche until menopause in otherwise eligible individuals [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">
          "Contraception: Counseling and selection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H739531375">
         <span class="h2">
          Blood pressure monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         For individuals without hypertension and without CVD or CVD risk factors, routine blood pressure evaluation at annual follow-up visits is appropriate.
        </p>
        <p>
         For individuals at higher risk of developing hypertension, such as individuals with a history of hypertension of pregnancy, we check blood pressure approximately three months after initiating estrogen-containing therapy. Blood pressure evaluation can be performed through out-of-office or in-office measurement. (See
         <a class="medical medical_review" href="/z/d/html/3879.html" rel="external">
          "Blood pressure measurement in the diagnosis and management of hypertension in adults", section on 'Our approach to measuring blood pressure'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If blood pressure becomes elevated while taking an estrogen-containing contraceptive, we typically discontinue it and offer non-estrogen containing hormonal contraceptive options, including a POP, a levonorgestrel-releasing IUD, or a progestin implant. (See
         <a class="medical medical_review" href="/z/d/html/5461.html" rel="external">
          "Contraception: Progestin-only pills (POPs)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">
          "Intrauterine contraception: Background and device types"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">
          "Contraception: Etonogestrel implant"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If hypertension persists, we discontinue all hormonal agents, offer nonhormonal contraception (eg,
         <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">
          copper IUD
         </a>
         , diaphragm), and monitor blood pressure to ensure return to pretreatment values.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If elevated blood pressure persists, further evaluation and management is warranted. (See
         <a class="medical medical_review" href="/z/d/html/3849.html" rel="external">
          "Initial evaluation of adults with hypertension"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3852.html" rel="external">
          "Overview of hypertension in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H865324921">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112268.html" rel="external">
          "Society guideline links: Contraception"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/109601.html" rel="external">
          "Society guideline links: Hypertension in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13075887">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition of hypertension for contraceptive purposes
         </strong>
         – When selecting contraception, individuals with hypertension are those with a systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg  (
         <a class="graphic graphic_table graphicRef131445" href="/z/d/graphic/131445.html" rel="external">
          table 1
         </a>
         ). While some organizations use a hypertension threshold of systolic ≥130 mmHg or diastolic ≥80 mmHg, data are lacking with regard to contraception and blood pressure in those with systolic pressure 130 to 139 mmHg or diastolic pressure 80 to 89 mmHg. (See
         <a class="local">
          'Definition of hypertension'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impact of hormones on blood pressure
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Estrogen-containing contraceptives
         </strong>
         – Pharmacologic levels of estrogen, such as those found in contraceptives  (
         <a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">
          table 5
         </a>
         ), can increase blood pressure in some individuals. Physiologic levels of estrogen, such as those found in hormone therapy for menopause, do not impact blood pressure.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Oral estrogens
         </strong>
         – Based on data from users of oral estrogen-progestin contraceptive pills, any rise in blood pressure while taking oral pills is usually mild, although some individuals may have more significant increases in blood pressure, and hypertensive emergencies may rarely occur. (See
         <a class="local">
          'Impact on blood pressure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Impact of non-oral estrogens
         </strong>
         – Non-oral estrogen-progestin hormonal contraceptives, including vaginal rings, transdermal contraceptive patches, and combined estrogen-progesterone injections (available outside of the United States and Canada) may have a more modest impact on blood pressure, although available data are limited. (See
         <a class="local">
          'Impact on blood pressure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Mechanism of action
         </strong>
         – The renin-angiotensin system (RAS) may be involved since estrogen stimulates the hepatic production of renin substrate (angiotensinogen). The sympathetic nervous system may also be activated. (See
         <a class="local">
          'Impact on blood pressure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Progestin-only contraceptives
         </strong>
         – Progestin-only contraceptives, which include implants, levonorgestrel-releasing intrauterine devices (IUDs), depot
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         (DMPA) injection, and progestin-only pills (POP)  (
         <a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">
          table 5
         </a>
         ), are generally not associated with elevations in blood pressure, although some may impact other cardiovascular risks. (See
         <a class="local">
          'Progestins'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient assessment
         </strong>
         – For individuals who desire contraception, initial evaluation includes assessment of other medical conditions and comorbidities, including blood pressure measurement, comparison of risks of hormonal contraceptives with the risks of pregnancy itself, and identification of those with unacceptable risks for hormonal contraceptive methods. We, and other experts, use the Centers for Disease Control and Prevention (CDC)'s
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=3827" target="_blank">
          Summary Chart of US Medical Eligibility Criteria
         </a>
         and the World Health Organization (WHO)
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F181468%2F9789241549158_eng.pdf%3Fsequence%3D9&amp;token=6nhhnZb0mtkVJwS3WOakPA5w7GkgerBCs7nrlFUitrR39lCGuBWfNLRXexATvnXkkXhjZwURagZbVOoo0qtiepjUv8Riew8Ltoc8ATBTzvUodc7F1ZodE778QnzeChim&amp;TOPIC_ID=3827" target="_blank">
          Medical Eligibility Criteria for Contraceptive Use 2015
         </a>
         comprehensive tables of medical conditions and personal characteristics to help guide contraceptive choice. (See
         <a class="local">
          'Evaluation of patients with hypertension'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Controlled hypertension
         </strong>
         – Many individuals with hypertension can safely take hormonal contraception, even if they take antihypertensive medication, provided their blood pressure is controlled (ie, blood pressure &lt;140/90 mm/Hg with medication). (See
         <a class="local">
          'Controlled hypertension'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          &lt;40 years
         </strong>
         – Individuals who are &lt;40 years of age with adequately controlled hypertension (ie, &lt;140/90 mmHg), who are otherwise healthy, and who do not have other cardiovascular disease (CVD) risk factors or established CVD, may be offered any contraceptive method. (See
         <a class="local">
          'Age &lt;40 years'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          ≥40 years
         </strong>
         – For individuals ≥40 years with controlled hypertension who desire hormonal contraception, we offer progestin-only contraceptives rather than estrogen-containing methods. These patients may use levonorgestrel-releasing IUDs, progestin implants, and POPs, in addition to all nonhormonal contraceptive methods, without restriction. The benefits of
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         in this population are generally thought to outweigh the theoretical risks of thromboembolism and altered lipid profile. Combined estrogen-progestin contraceptives are generally avoided in these patients because of concerns for increased risk of thromboembolic events. However, select individuals in this group may be offered estrogen-containing contraceptives if they are expected to obtain additional benefits from these agents, provided they receive careful counseling and follow-up. (See
         <a class="local">
          'Age ≥40 years'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Uncontrolled hypertension
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For individuals of any age with uncontrolled hypertension (blood pressure ≥140/90 mmHg, including those with poorly controlled hypertension [ie, blood pressure ≥160/100 mmHg]), further evaluation and management of hypertension is warranted.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Individuals of any age with hypertension (blood pressure ≥140/90 mmHg, including those with poorly controlled hypertension [ie, blood pressure ≥160/100 mmHg]) may use any
         <strong>
          non
         </strong>
         hormonal contraceptive without restriction. The nonhormonal
         <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">
          copper IUD
         </a>
         (copper 380 mm
         <sup>
          2
         </sup>
         IUD) does not impact blood pressure and is one of the most effective contraceptive options  (
         <a class="graphic graphic_figure graphicRef119765" href="/z/d/graphic/119765.html" rel="external">
          figure 1
         </a>
         ). Other nonhormonal options include condoms (external or internal), diaphragms, and cervical caps.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Individuals with uncontrolled hypertension (blood pressure ≥140/90 but ≤159/99 mmHg) who desire hormonal contraception are offered progestin-only contraceptives, including the
         <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">
          levonorgestrel IUDs
         </a>
         , or nonhormonal contraceptives, rather than estrogen-containing contraceptives. However, select individuals in this group may be offered estrogen-containing contraceptives if they have blood pressure in the lower end of this range, are expected to obtain additional benefits from estrogen-containing contraceptives, and receive careful counseling and follow-up.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We do
         <strong>
          not
         </strong>
         use estrogen-containing contraceptives (oral pills, transdermal patches, vaginal rings, and injections) for individuals with poorly controlled hypertension (ie, blood pressure ≥160/100 mmHg) because of increased risk of cardiovascular event in these patients. (See
         <a class="local">
          'Uncontrolled hypertension'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Cardiovascular effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Individuals without hypertension
         </strong>
         – For patients with normal (systolic &lt;120 mmHg and diastolic &lt;80 mmHg) and elevated blood pressure (systolic 120 to 129 mmHg and diastolic &lt;80 mmHg) blood pressure, the development of hypertension is unusual with contraceptives containing lower doses of estrogen (ie, ≤35 mcg estradiol or equivalent); the benefits of these agents generally outweigh the potential risk of medication-induced hypertension. Routine blood pressure evaluation at annual follow-up visits is appropriate. (See
         <a class="local">
          'Individuals without hypertension'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.
          </a>
         </li>
         <li class="breakAll">
          Medical eligibility criteria for contraceptive use, 5th ed. World Health Organization, 2015. https://www.who.int/publications/i/item/9789241549158.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godsland IF, Crook D, Devenport M, Wynn V. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease. Contraception 1995; 52:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71:e13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qaseem A, Wilt TJ, Rich R, et al. Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2017; 166:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018; 36:1953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ACOG Practice Bulletin No. 206: Use of Hormonal Contraception in Women With Coexisting Medical Conditions. Obstet Gynecol 2019; 133:e128. Reaffirmed 2022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens 2023; 41:1874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gijón-Conde T, Sánchez-Martínez M, Graciani A, et al. Impact of the European and American guidelines on hypertension prevalence, treatment, and cardiometabolic goals. J Hypertens 2019; 37:1393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chasan-Taber L, Willett WC, Manson JE, et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996; 94:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim KG, Isles CG, Hodsman GP, et al. Malignant hypertension in women of childbearing age and its relation to the contraceptive pill. Br Med J (Clin Res Ed) 1987; 294:1057.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shufelt CL, Bairey Merz CN. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol 2009; 53:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cardoso F, Polónia J, Santos A, et al. Low-dose oral contraceptives and 24-hour ambulatory blood pressure. Int J Gynaecol Obstet 1997; 59:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weir RJ, Briggs E, Mack A, et al. Blood pressure in women taking oral contraceptives. Br Med J 1974; 1:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisch IR, Frank J. Oral contraceptives and blood pressure. JAMA 1977; 237:2499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meade TW, Haines AP, North WR, et al. Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen. Lancet 1977; 2:948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson ES, Cruickshank J, McMaster M, Weir RJ. A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestogen. Br J Obstet Gynaecol 1984; 91:1254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boldo A, White WB. Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies. Endocrinol Metab Clin North Am 2011; 40:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giribela CR, Consolim-Colombo FM, Nisenbaum MG, et al. Effects of a combined oral contraceptive containing 20 mcg of ethinylestradiol and 3 mg of drospirenone on the blood pressure, renin-angiotensin-aldosterone system, insulin resistance, and androgenic profile of healthy young women. Gynecol Endocrinol 2015; 31:912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Morais TL, Giribela C, Nisenbaum MG, et al. Effects of a contraceptive containing drospirenone and ethinylestradiol on blood pressure, metabolic profile and neurohumoral axis in hypertensive women at reproductive age. Eur J Obstet Gynecol Reprod Biol 2014; 182:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woods JW. Oral contraceptives and hypertension. Hypertension 1988; 11:II11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldhaber SZ, Hennekens CH, Spark RF, et al. Plasma renin substrate, renin activity, and aldosterone levels in a sample of oral contraceptive users from a community survey. Am Heart J 1984; 107:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harvey RE, Hart EC, Charkoudian N, et al. Oral Contraceptive Use, Muscle Sympathetic Nerve Activity, and Systemic Hemodynamics in Young Women. Hypertension 2015; 66:590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aisien AO, Enosolease ME. Safety, efficacy and acceptability of implanon a single rod implantable contraceptive (etonogestrel) in University of Benin Teaching Hospital. Niger J Clin Pract 2010; 13:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorflinger LJ. Metabolic effects of implantable steroid contraceptives for women. Contraception 2002; 65:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995; 273:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kling JM, Lahr BA, Bailey KR, et al. Endothelial function in women of the Kronos Early Estrogen Prevention Study. Climacteric 2015; 18:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang X, Aragaki AK, Nudy M, et al. The association of hormone therapy with blood pressure control in postmenopausal women with hypertension: a secondary analysis of the Women's Health Initiative clinical trials. Menopause 2023; 30:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalenga CZ, Metcalfe A, Robert M, et al. Association Between the Route of Administration and Formulation of Estrogen Therapy and Hypertension Risk in Postmenopausal Women: A Prospective Population-Based Study. Hypertension 2023; 80:1463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindley KJ, Teal SB. Contraception in Women With Cardiovascular Disease. JAMA 2022; 328:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danvers AA, Gurney EG, Panushka KA, et al. Shortcomings and disparities in contraception counseling and use by hypertensive individuals at risk for unintended pregnancy: a comparative analysis of the National Survey of Family Growth. Am J Obstet Gynecol 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vessey M, Painter R, Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. Lancet 2003; 362:185.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3827 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7587185" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29133356" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28135725" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30234752" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30681544" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : ACOG Practice Bulletin No. 206: Use of Hormonal Contraception in Women With Coexisting Medical Conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37345492" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31145710" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Impact of the European and American guidelines on hypertension prevalence, treatment, and cardiometabolic goals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8759093" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Prospective study of oral contraceptives and hypertension among women in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3107691" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Malignant hypertension in women of childbearing age and its relation to the contraceptive pill.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19147038" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Contraceptive hormone use and cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9486514" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Low-dose oral contraceptives and 24-hour ambulatory blood pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4817186" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Blood pressure in women taking oral contraceptives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/576962" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Oral contraceptives and blood pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/72289" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6440589" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21565676" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26172927" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Effects of a combined oral contraceptive containing 20 mcg of ethinylestradiol and 3 mg of drospirenone on the blood pressure, renin-angiotensin-aldosterone system, insulin resistance, and androgenic profile of healthy young women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25268778" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Effects of a contraceptive containing drospirenone and ethinylestradiol on blood pressure, metabolic profile and neurohumoral axis in hypertensive women at reproductive age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3280486" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Oral contraceptives and hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6362381" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Plasma renin substrate, renin activity, and aldosterone levels in a sample of oral contraceptive users from a community survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26101348" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Oral Contraceptive Use, Muscle Sympathetic Nerve Activity, and Systemic Hemodynamics in Young Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20857796" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Safety, efficacy and acceptability of implanon a single rod implantable contraceptive (etonogestrel) in University of Benin Teaching Hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11861055" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Metabolic effects of implantable steroid contraceptives for women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12117397" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7807658" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25417709" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Endothelial function in women of the Kronos Early Estrogen Prevention Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36256926" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The association of hormone therapy with blood pressure control in postmenopausal women with hypertension: a secondary analysis of the Women's Health Initiative clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37272379" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Association Between the Route of Administration and Formulation of Estrogen Therapy and Hypertension Risk in Postmenopausal Women: A Prospective Population-Based Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35867075" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Contraception in Women With Cardiovascular Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37871872" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Shortcomings and disparities in contraception counseling and use by hypertensive individuals at risk for unintended pregnancy: a comparative analysis of the National Survey of Family Growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12885478" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Mortality in relation to oral contraceptive use and cigarette smoking.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
